Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Sources Sought opportunity from Department Of Health And Human Services was posted on May 4, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Metabolism Qualified Cryopreserved Human Hepatocytes

Closed
FDASSN132690Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
DIBBS
Measles, Mumps, and Rubella (MMR) Vaccine Supply and DeliveryThe contract entails the supply and delivery of three units of Measles, Mumps, and Rubella vaccine to a U.S. Navy vessel at a forward operating base destination, with strict requirements for traceable express shipping and full compliance with established medical handling standards. The contractor is responsible for ensuring the vaccines remain viable throughout transit by adhering to temperature control, packaging, and documentation protocols mandated for biological materials. This is a subcontract under the Department of Defense, managed by the Defense Logistics Agency, with a NAICS code of 325414 indicating pharmaceutical preparation manufacturing. The delivery must be completed in accordance with military logistics guidelines, and all shipping records must maintain a verifiable chain of custody from origin to final receipt aboard the vessel. The contract was posted on August 9, 2026, and the place of performance is tied to a military operational location, though specific geographic details are not provided. The award reference number SPE2DX25D8022 and delivery identifier SPE2D926F8119 are linked to the official DLA procurement system, underscoring the mission-critical nature of timely and secure delivery. While the solicitation number is not listed, the subcontract structure suggests coordination with a prime contractor to fulfill the DOD’s medical readiness requirements. All activities must comply with federal regulations governing vaccine distribution and military supply chain integrity.
Defense Logistics Agency

POSTED

about 1 month ago

DEADLINE

N/A

AI Contract Overview

Show more

The U.S. Food and Drug Administration is seeking information on the availability of qualified small business suppliers capable of providing metabolism-qualified cryopreserved human hepatocytes and associated materials for mission-critical regulatory science research. The requirement specifies the delivery of 24 vials of cryopreserved hepatocytes from four distinct female donors—six vials per donor—with specific demographic criteria: one donor aged 20–35 years and three donors aged 54–70 years, all of U.S. origin and testing negative for HIV and Hepatitis B/C, with available CMV and EBV results. Each vial must contain a minimum of five million viable cells with at least 85% viability post-thaw and must be qualified for key metabolic enzymes including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The cells must be plateable in 12-well plates and remain functional for four to five days after plating. The supplier must also provide thawing and culturing protocols in PDF format, including detailed media compositions and sourcing, along with thawing media, incubation media, antibiotic mix if applicable, and a cryogenic shipping container for safe transport. Each donor lot must be accompanied by a Certificate of Analysis and comprehensive donor information such as age, sex, race/ethnicity, cause of death, substance use history, and liver-related medical conditions. All materials must be shipped using dry ice or liquid nitrogen and delivered to the FDA’s facility in Silver Spring, Maryland, within seven days of award, Monday through Friday between 9 a.m. and 3 p.m., excluding federal holidays. Delivery must be coordinated in advance with the designated point of contact. Responses, limited to ten pages, must include the company’s business size classification under NAICS code 325414, which has a small business threshold of 1,250 employees, as well as its SAM.gov Unique Entity Identifier. This notice is solely for market research and does not constitute a solicitation or binding obligation for the government. No questions will be entertained, and no feedback will be provided to respondents.

General Info

FDA seeks small businesses to supply metabolism-qualified cryopreserved human hepatocytes and related materials.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant SvcsView Agency

NAICS

325414 - Biological Product (except Diagnostic) ManufacturingView NAICS

Place of Performance

MD, 20862, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

Sources Sought

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs
Contacts2 people available
OfficeRockville, MD, 20852, USA
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
View Agency Profile
Office AddressRockville, MD, 20852, USA
Contacts

Full Description

Show more

This is a Food and Drug Administration (FDA) Small Business Sources Sought Notice for Commercial Supplies. This is NOT a solicitation for proposals, proposal abstracts, or quotations.


The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition is 325414; Biological Product (except Diagnostic) Manufacturing, with a small business standard size of 1,250 employees. The Product Service Code (PSC) is 6505: Drugs and Biologicals.


Responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code is still encouraged to submit a Capabilities Statement.


**QUESTIONS WILL NOT BE ENTERTAINED AS A RESULT OF THIS NOTICE**


BACKGROUND


The United States Food and Drug Administration (FDA) has a mission to protect public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. In addition, FDA is responsible for facilitating innovations that make medicines more effective, safer, and more affordable. To accomplish these goals, FDA has stimulated advancement of regulatory science, which is defined as “the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA regulated products.” FDA’s vision is to facilitate the integration of new science into the process of evaluating the safety and efficacy of proposed and marketed products and to close the gap between scientific innovation and this process of drug review. To achieve this vision, we perform mission-critical research to develop and evaluate tools, standards, and approaches to assess the safety, efficacy, quality, and performance of drugs.


The Division of Applied Regulatory Science (DARS) is conducting a research project to examine the effect of female sex hormones on in vitro drug metabolism. DARS operates several labs that provide mission- critical research supporting review questions, translational science, and emerging public health issues for Center for Drug Evaluation and Research (CDER) and FDA. We develop and evaluate novel tools, standards, and approaches that increase the regulatory efficiency of developing and reviewing safe and effective CDER products. These operational supplies are essential for the continuance of these projects across our labs, and for continued preparedness to be able to respond to emergent public health issues when called upon.


OBJECTIVE


The supplier is to provide protocol(s) for the thawing, plating and culturing the hepatocytes. This is to include the media composition and source for all these stages for the hepatocytes. The supplier will provide up to a total of 24 vials of cryopreserved human hepatocytes from 4 different female donors. Additionally, thawing and incubation media is required for the hepatocyte cultures.


PROJECT REQUIREMENTS


The U.S. Food and Drug Administration (FDA), Office of Clinical Pharmacology (OCP), Division of Applied Regulatory Science (DARS), requires metabolism-qualified cryopreserved human hepatocytes and associated materials to support mission-critical regulatory science research.


TECHNICAL REQUIREMENT SUMMARY


Respondents shall demonstrate the ability to provide cryopreserved human hepatocytes that meet the following requirements:


DONOR REQUIREMENTS


  • Four (4) single-donor lots (not pooled)
  • Donor demographics:
    • One (1) donor aged 20–35 years
    • Three (3) donors aged 54–70 years
  • Donors must be:
    • Of U.S. origin
    • Negative for HIV and Hepatitis B/C
    • With available CMV and EBV test results

CELL QUALITY REQUIREMENTS


  • Minimum 5 million viable hepatocytes per vial
  • Minimum ≥85% viability post-thaw
  • Must be metabolism-qualified, including:
    • CYP1A2
    • CYP2B6
    • CYP2C9
    • CYP2C19
    • CYP2D6
    • CYP3A4
  • Must be:
    • Plateable in multi-well plates (12-well format)
    • Functional for 4–5 days post-plating

DOCUMENTATION REQUIREMENTS


Each donor lot must include:


  • Certificate of Analysis (CoA) or equivalent
  • Donor information (as available):
    • Age, sex, race/ethnicity
    • Cause of death
    • Substance use history
    • Liver-related medical conditions
  • Metabolism activity data
  • Biosafety information

DELIVERABLES


The contractor shall provide:


  • 24 total vials (6 vials per donor lot × 4 donors)
  • Associated materials, including:
    • Thawing media
    • Incubation/culture media
    • Antibiotic mix (if applicable)
  • Cryogenic shipping container (e.g., cryoshipper)

PROTOCOL REQUIREMENTS


The contractor shall provide protocol documentation (PDF format) prior to shipment, including:


  • Thawing procedures
  • Plating procedures
  • Culture conditions
  • Media composition and sourcing

SHIPPING & DELIVERY REQUIREMENTS


  • Shipment must maintain product integrity using:
    • Dry ice or liquid nitrogen
  • Delivery must occur:
    • Within 7 days of award
    • Monday–Friday, 9:00 AM – 3:00 PM (excluding federal holidays)
  • Delivery location:

U.S. Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993


  • Delivery must be coordinated in advance with the Government POC

PERIOD OF PERFORMANCE


The anticipated period of performance is six (6) months from date of award.


CAPABILITIES AND TECHNICAL EXPERIENCE


Provide a capability statement describing how your company would be able to meet the requirements.


BUSINESS STATUS


Please provide your business size status (e.g., small business, 8(a), HUBZone, etc.) and SAM.gov Unique Entity Identifier (UEI) number.


DISCLAIMER AND IMPORTANT NOTES


This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work.


Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation.

Responses to the sources sought shall be no longer than 10 pages.

More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

Same awarding agency

NAICS: 541714
New
Federal
Human Hindbrain Organoid Functional Assay Services.
Solicitation # RFQ_CDR-2026-135968
The U.S. Food and Drug Administration, through the Center for Drug Evaluation and Research, intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services. This acquisition, conducted under FAR Part 12 as a commercial service, aims to support in vitro research on drug-induced effects on respiratory-relevant neural circuits. The scope of work includes the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 18 hours ago

DEADLINE

in 5 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS